FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
13.0 pt (24h)Health & MedicineOne-Off3m
KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiDiscretamente calibratoProbabilità implicita attuale
Sì 98%+13.0pt
Qualità del mercato
47 / 100
Bassa qualitàVolume 24h
480,1 €
Liquidità
1,3K €
Bassa liquiditàBid / Ask
91.0% / 99.0%
Spread
8.0 pt
Spread ampioDati di mercato
Aggiornato 6 minuti fa
17 giu 26, 21:30 UTC1 gen 27, 04:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegole
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Si regola tramite:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in.
- It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma.
- In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.
Mercati aperti
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume totale
- 15,6 Mln €
- Volume 24h
- 18,3K €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volume totale
- 1,6 Mln €
- Volume 24h
- 5,2K €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 altri esiti
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volume totale
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volume totale
- 916K €
- Volume 24h
- 1,5K €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 altri esiti
- Volume totale
- 863,6K €
- Volume 24h
- 1K €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Domande frequenti
- Quali sono le probabilità attuali per FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- Kalshi quota Yes al 98% al 8 settembre 2026.
- Quando si risolve FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) dovrebbe risolversi il 1 gennaio 2027.
- Come viene liquidato FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- Kalshi liquida questo mercato come segue: If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.